Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: Choice of dose and phenotypic trait measure

Journal of Clinical Pharmacology

Volumn 38, Issue 1, 1998, Pages 82-89

  Frye, Reginald F ^a   Adedoyin, Adedayo ^a   Mauro, Kelly ^a   Matzke, Gary R ^a   Branch, Robert A ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORZOXAZONE; DIMETHYLNITROSAMINE DEMETHYLASE; DRUG METABOLITE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL;

EID: 0031909513     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04381.x     Document Type: Article

References (26)

1. Yang CS, Smith T, Ishizaki H, Hong JY: Enzyme mechanisms in the metabolism of nitrosamines. IARC Sci Publ 1991;105:265-274.
2. Yang CS, Yoo JS, Ishizaki H, Hong JY: Cytochrome P450IIE1: roles in nitrosamine metabolism and mechanisms of regulation. Drug Metab Rev 1990;22:147-159.
3. Koop DR: Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB J 1992;6:724-730.
4. Guengerich FP, Kim DH, Iwasaki M: Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991;4:168-179.
5. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS: Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 1990;3:566-573.
6. Zand R, Nelson SD, Slattery JT, Thummel KE, Kalhorn TF, Adams SP, et al: Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans. Clin Pharmacol Ther 1993;54:142-149.
7. Kim RB, O'Shea D, Wilkinson GR: Relationship in healthy subjects between CYP2E1 genetic polymorphisms and the 6-hydroxylation of chlorzoxazone: a putative measure of CYP2E1 activity. Pharmacogenetics 1994;4:162-165.
8. Dreisbach AW, Ferencz N, Hopkins NE, Fuentes MG, Rege AB, George WJ, et al: Urinary excretion of 6-hydroxychlorzoxazone as an index of CYP2E1 activity. Clin Pharmacol Ther 1995;58:498-505.
9. Girre C, Lucas D, Hispard E, Menez C, Dally S, Menez JF: Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem Pharmacol 1994;47:1503-1508.
10. Lucas D, Berthou F, Girre C, Poitrenaud F, Menez JF: High-performance liquid chromatographic determination of chlorzoxazone and 6-hydroxychlorzoxazone in serum: a tool for indirect evaluation of cytochrome P4502E1 activity in humans. J Chromatogr 1993;622:79-86.
11. Kim RB, Yamazaki H, Chiba K, O'Shea D, Mimura M, Guengerich FP, et al: In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. J Pharmacol Exp Ther 1996;279:4-11.
12. Kim RB, O'Shea D, Wilkinson GR: Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther 1995;57:645-655.
13. Kharasch ED, Thummel KE, Mhyre J, Liilibridge JH: Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1. Clin Pharmacol Ther 1993;53:643-650.
14. Desiraju RK, Renzi NL, Nayak RK, Ng KT: Pharmacokinetics of chlorzoxazone in humans. J Pharm Sci 1983;72:991-994.
15. O'Shea D, Davis SN, Kim RB, Wilkinson GR: Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 1994;56:359-367.
16. Vesell ES, Seaton TA, Arahira YI: Studies on interindividual variations of CYP2E1 using chlorzoxazone as an in vivo probe. Pharmacogenetics 1995;5:53-57.
17. De Vries JD, Salphati L, Horie S, Becker CE, Hoener BA: Variability in the disposition of chlorzoxazone. Biopharm Drug Dispos 1994;15:587-597.
18. Frye RF, Stiff DD: Determination of chlorzoxazone and 6-hydroxychlorzoxazone in human plasma and urine by high-performance liquid chromatography. J Chromatogr B Bio Med Appl 1996;686:291-296.
19. Raucy JE, Lasker JM, Lieber CS, Black M: Acetaminophen activation by human liver cytochromes P450 IIE1 and P450 IA2. Arch Biochem Biophys 1989;271:270-283.
20. Tsutsumi M, Takada A, Wang JS: Genetic polymorphisms of cytochrome P4502E1 related to the development of alcoholic liver disease. Gastroenterology 1994;107:1430-1435.
21. Yamazaki H, Guo Z, Guengerich FP: Selectivity of cytochrome P4502E1 in chlorzoxazone 6-hydroxylation. Drug Metab Dispos 1995;23:438-440.
22. Dreisbach AW, Ferencz N, Hopkins NE, Fuentes MG, Rege AB, George WJ, et al: Urinary excretion of 6-OH-chlorzoxazone (CZX-OH) is formation rate limited (abstract). Clin Pharmacol Ther 1995;57:217.
23. Kedderis GL, Batra R, Koop DR: Epoxidation of acrylonitrile by rat and human cytochromes P450. Chem Res Toxicol 1993;6:866-871.
24. Dreisbach AW, Ferencz N, Hopkins NE, Rege AB, George WJ, Lertora JJL: Hydroxylation index for chlorzoxazone as a measure of cytochrome P4502E1 activity (abstract). Clin Res 1993;41:758A.
25. Dreisbach AW, Ferencz N, Hopkins NE, Rege AB, George WJ, Lertora JJL: Urinary excretion of 6-OH-chlorzoxazone as an index of cytochrome P4502E1 activity (abstract). Clin Pharmacol Ther 1994;55:140.
26. Twele VR, Spiteller G: Identifizierung von chlorzoxazon-metaboliten im menschlichen urin. Arzneim Forsch Drug Res 1982;32:759-763.